Core Insights - Propanc Biopharma, Inc. is investigating "mesenchymal drift" to understand the reversal of chronic diseases, particularly focusing on its lead product candidate, PRP, and its influence on epithelial-to-mesenchymal transition (EMT) pathways [1][3] - The company has filed a patent application for a PRP-based treatment method targeting fibrotic diseases, which are significant contributors to age-related organ failure [1][3] Company Overview - Propanc Biopharma, Inc. is developing innovative treatments aimed at preventing cancer recurrence and metastasis by targeting cancer stem cells through proenzyme activation [4] - The lead product candidate, PRP, consists of pancreatic proenzymes trypsinogen and chymotrypsinogen, which are administered intravenously [3][4] Research and Development - A Phase 1b First-In-Human study for PRP in patients with advanced solid tumors is scheduled to begin in 2026, focusing on determining the maximum tolerated dose [3] - Following the initial study, multiple Phase 2 proof-of-concept trials will be conducted to explore various indications, with the potential to achieve "blockbuster status" [3] Scientific Collaboration - The research team includes experts from Propanc and the University of Jaén, emphasizing the importance of PRP in addressing chronic diseases like cancer and fibrosis [3] - The investigation into PRP's effects on EMT and mesenchymal drift is seen as a promising direction for developing new rejuvenation strategies in medicine [3]